Meme Kanserinin Önlenmesinde Profilaktik Mastektomi

Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science; 1994; 266: 66–71. doi: 10.1038/bjc.2017.415
Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378: 789–792. doi: 10.1016/j.breast.2017.09.003
Janjan NA, Zellmer DL. Calculated risk of breast cancer following mantle irradiation determined by measured dose. Cancer Detect Prev. 1992;16: 273–282. doi: 10.1093/jnci/djv263
Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29: 1664–1669. doi: 10.1001/jamaoncol.2018.0695
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998; 90: 1371–1388. doi: 10.1016/j.breast.2019.07.006
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22: 1055–1062. doi: 10.1007/s10549-019-05143-5
Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol. 2010;7: 702–707. doi: 10.1001/jamaoncol.2019.0826
Filippini SE, Vega A. Breast cancer genes: beyond BRCA1 and BRCA2. Front Biosci (Landmark Ed). 2012;18: 1358–1372. doi: 10.1200/JCO.2018.80.8434
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25: 1329–1333. doi: 10.1200/JCO.2016.70.3226
Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA- mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144: 443–455. doi: 10.1158/1078-0432.CCR-16-0058
Verhoog LC, Brekelmans CT, Seynaeve C, et al. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 2000;83: 384–386. doi: 10.1093/jnci/djv003
Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004; 22: 2328–2335. doi: 10.1093/jnci/djv135
Green L, Meric-Bernstam F. Risk of ipsilateral and contralateral cancer in BRCA mutation carriers with breast cancer. Curr Breast Cancer Rep. 2011;3: 151–155. doi: 10.1001/jamaoncol.2018.1612
Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18: 400–407. doi: 10.1002/cncr.31881
Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med. 1998;128: 896–899. doi: 10.1200/JCO.2018.78.5977
Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52: 2984–2986. doi: 10.1016/j.breast.2019.02.014
Euhus D. Genetic testing today. Ann Surg Oncol. 2014;21: 3209–3215. doi: 10.1001/jama.2016.13446
Oppong BA, King TA. Recommendations for women with lobular carcinoma in situ (LCIS). Oncology (Williston Park). 2011;25: 1051–1058. doi: 10.1200/JCO.2016.69.3737
Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23: 5534–5541. doi: 10.1007/s10549-019-05213-8
Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42: 737–769. doi: 10.1200/JCO.2016.70.8297
Oskar S, Muhsen S, Sung J, et al. Chemoprevention among women with lobular carcinoma in situ. Ann Surg Oncol. 2011;18: 59. doi: 10.1200/JCO.2017.73.7735
Bunting PW, Cyr AE, Gao F, et al. Sentinel lymph node biopsy during prophylactic mastectomy: is there a role? J Surg Oncol. 2014;109: 747–750. doi: 10.1001/jama.2017.19135
Grobmyer SR, Mortellaro VE, Marshall, et al. Is there a role for routine use of MRI in selection of patients for breast-conserving cancer therapy? J Am Coll Surg. 2008;206: 1045–1050. doi: 10.1093/annonc/mdw601
King TA, Gurevich I, Sakr R, et al. Occult malignancy in patients undergoing contra- lateral prophylactic mastectomy. Ann Surg. 2011;254: 2–7. doi: 10.1038/ncomms14241
Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29: 1564–1569. doi: 10.1038/bjc.2016.304
Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995;13: 1578–1583. doi: 10.1200/JCO.2016.69.1066
Black WC, Nease RF Jr, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995;87: 720–731. doi: 10.1007/s10549-019-05122-w
Alexander NE, Ross J, Sumner W, et al. The effect of an educational intervention on the perceived risk of breast cancer. J Gen Intern Med. 1996;11: 92–97. doi: 10.1158/1078-0432.CCR-18-1902
Rosenberg SM, Partridge AH. Contralateral prophylactic mastectomy: an opportunity for shared decision making. JAMA Surg. 2014;149(6): 589–590. doi: 10.1001/jama.2015.1937
Wainberg S, Husted J. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev. 2004;13: 1989–1995. doi: 10.1007/s10549-019-05196-7
Skytte AB, Gerdes AM, Andersen MK, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010;77: 342–349. doi: 10.1007/s10549-019-05216-6
Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122: 2017–2022. doi: 10.1002/cncr.29998
Beattie MS, Crawford B, Lin F, et al. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers. 2009;13: 51–56. doi: 10.1093/jnci/djv372
Goldschmidt RA, Victor TA. Lobular carcinoma in situ of the breast. Semin Surg Oncol. 1996;12: 314–320. doi: 10.1038/bjc.2017.294
Burke EE, Portschy PR, Tuttle TM. Prophylactic mastectomy: who needs it, when and why. J Surg Oncol. 2014;111(1): 91–95. doi: 10.1093/jnci/dju289
Portschy PR, Marmor S, Nzara R, et al. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis. Ann Surg Oncol. 2013;20: 3240–3246. doi: 10.1093/annonc/mdw501
Newman LA. Contralateral prophylactic mastectomy: is it a reasonable option? JAMA. 2014;312: 895–897. doi: 10.1200/JCO.2015.64.8674
Kurian AW, Lichtensztajn DY, Keegan TH, et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA. 2014;312: 902–914. doi: 10.1093/jnci/djv135
King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29: 2158–2164. doi: 10.1200/JCO.2016.69.9520
Guth U, Myrick ME, Viehl CT, et al. Increasing rates of contralateral prophylactic mastectomy – a trend made in USA? Eur J Surg Oncol. 2012;38: 296–301. doi: 10.1200/JCO.2015.61.8908
Den Heijer M, van Asperen CJ, Harris H, et al. International variation in physicians’ attitudes towards prophylactic mastectomy – comparison between France, Germany, the Netherlands and the United Kingdom. Eur J Cancer. 2013;49: 2798–2805. doi: 10.1093/annonc/mdv317
Crowe JP Jr, Kim JA, Yetman R, et al. Nipple-sparing mastectomy: technique and results of 54 procedures. Arch Surg. 2004;139: 148–150. doi: 10.1093/annonc/mdv172
Kronowitz SJ. Delayed-immediate breast reconstruction: technical and timing considerations. Plast Reconstr Surg. 2010;125: 463–474. doi: 10.1093/annonc/mdw544
Semple J, Metcalfe KA, Lynch HT, et al. International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. Ann Surg Oncol. 2013;20: 3817–3822. doi: 10.1245/s10434-013-3213-3
Garcia-Etienne CA, Cody III HS, Disa JJ, et al. Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. Breast J. 2009;15: 440–449. doi: 10.1111/tbj.12302
Reynolds C, Davidson JA, Lindor NM, et al. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved? Ann Surg Oncol. 2011;18: 3102–3109. doi: 10.1245/s10434-011-1751-4
Peled AW, Irwin CS, Hwang ES, et al. Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol. 2014;21: 37–41. doi: 10.1245/s10434-013-3282-2
McLaughlin SA, Stempel M, Morris EA, et al. Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer. 2008;112: 1214–1221. doi: 10.1002/cncr.23330
Czyszczon IA, Roland L, Sahoo S. Routine prophylactic sentinel lymph node biopsy is not indicated in women undergoing prophylactic mastectomy. J Surg Oncol. 2012;105: 650–654. doi: 10.1002/jso.23211
Camp MS, Coopey SB, Tang R, et al.Management of positive sub-areolar/nipple duct margins in nipple-sparing mastectomies. Breast J. 2014;20: 402–407. doi: 10.1111/tbj.12272
Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004;101: 1977–1986. doi: 10.1002/cncr.20592
Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;11: CD002748. doi: 10.1002/14651858.CD002748.pub4

Eck DL, Perdikis G, Rawal B, et al. Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy. Ann Surg Oncol. 2014;21: 3297–3303. doi: 10.1245/s10434-014-3676-5
Miller ME, Czechura T, Martz B, et al. Operative risks associated with contralateral prophylactic mastectomy: a single institution experience. Ann Surg Oncol. 2013;20: 4113–4120. doi: 10.1245/s10434-013-3232-0
Osman F, Saleh F, Jackson TD, et al. Increased postoperative complications in bilateral mastectomy patients compared to unilateral mastectomy: an analysis of the NSQIP database. Ann Surg Oncol. 2013;20: 3212–3217. doi: 10.1245/s10434-013-3045-7
Contant CM, Menke-Pluijmers MB, Seynaeve C, et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HBOC) or a proven BRCA1 and BRCA2 germ-line mutation. Eur J Surg Oncol. 2002; 28: 627–632. doi: 10.1053/ejso.2002.1297
Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304: 967–975. doi: 10.1001/jama.2010.1317
Kaas R, Verhoef S, Wesseling J, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 2010;251: 488–492. doi: 10.1016/j.amsu.2010.05.004
Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340: 77–84. doi: 10.1056/NEJM199901143400201
McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19: 3938–3943. doi: 10.1200/JCO.2001.19.18.3938
Narod SA. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat. 2011;128: 581–583. doi: 10.1007/s10549-011-1622-7
Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348: 226. doi: 10.1007/s10549-013-2837-4
Fayanju OM, Stoll CR, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg. 2014;260: 1000–1010. doi: 10.1097/SLA.0000000000000970
Yao K, Winchester DJ, Czechura T, et al. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002. Breast Cancer Res Treat. 2013;142: 465–476. doi: 10.1007/s10549-013-2741-1
Geiger AM, Nekhlyudov L, Herrinton LJ, et al. Quality of life after bilateral prophylactic mastectomy. Ann Surg Oncol. 2007;14: 686–694. doi: 10.1245/s10434-006-9133-z
Altschuler A, Nekhlyudov L, Rolnick SJ, et al. Positive, negative, and disparate – women’s differing long-term psychosocial experiences of bilateral or contralateral prophylac- tic mastectomy. Breast J. 2008;14: 25–32. doi: 10.1111/j.1524-4741.2008.00546.x
Tuttle TM, Abbott A, Arrington A, et al. The increasing use of prophylactic mastectomy in the prevention of breast cancer. Curr Oncol Rep. 2010;12: 16–21. doi: 10.1007/s11912-009-0082-2
Montgomery LL, Tran KN, Heelan MC, et al. Issues of regret in women with contra- lateral prophylactic mastectomies. Ann Surg Oncol 1999;6: 546–552. doi: 10.1007/s10434-999-0546-9
Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26: 3943–3949. doi: 10.1200/JCO.2008.17.1531
van Oostrom I, Meijers-Heijboer H, Lodder LN, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003;21: 3867–3874. doi: 10.1200/JCO.2003.03.078
Gahm J, Wickman M, Brandberg Y. Bilateral prophylactic mastectomy in women with inherited risk of breast cancer–prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Breast. 2010;19: 462–469. doi: 10.1016/j.breast.2010.05.011
Wasteson E, Sandelin K, Brandberg Y, et al. High satisfaction rate ten years after bilateral prophylactic mastectomy – a longitudinal study. Eur J Cancer Care (Engl). 2011;20: 508–513. doi: 10.1111/j.1365-2354.2010.01193.x
Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296: 185–192. doi: 10.1001/jama.296.2.185
Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91: 1475–1479. doi: 10.1093/jnci/91.17.1475
Kauff ND, Domchek SM, Friebel TM et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26: 1331–1337. doi: 10.1200/JCO.2007.13.9626
Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23: 7491–7496. doi: 10.1200/JCO.2005.01.9338
Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371: 497–506. doi: 10.1056/NEJMoa1400382
Goldgar DE, Healey S, Dowty JG, et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 2011;13: 73. doi: 10.1186/bcr2887
Lalloo F, Evans DG. Familial breast cancer. Clin Genet. 2012;82: 105–114. doi: 10.1111/j.1399-0004.2011.01706.x
Mester J, Eng C. Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol. 2015;111(1): 125–130. doi: 10.1002/jso.23875
Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12: 3209–3215. doi: 10.1158/1078-0432.CCR-05-2984